RxDoctor Payments Data

David Tobin, NP

Psychiatric/Mental Health · Detroit, MINPI 1992496921

Payments from drug & device makers

$5,229in general payments, 2019–2025

Across 317 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$734
  • Otsuka America Pharmaceutical, Inc.$628
  • Lundbeck LLC$433
  • Teva Pharmaceuticals USA, Inc.$374
  • Neurocrine Biosciences, Inc.$328
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,229 in reported general payments places this provider in the 90th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$11,724
Medicare patients
14
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate14$21,927
TrintellixVortioxetine Hydrobromide13$6,944
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$2,842
Lurasidone Hcl14$1,871
Quetiapine Fumarate82$871
Divalproex Sodium41$703
Fluoxetine Hcl87$686
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine39$631
Sertraline Hcl105$594
Trazodone Hcl58$477
Olanzapine49$430
Bupropion XlBupropion Hcl41$360
Escitalopram Oxalate50$345
Hydroxyzine Hcl18$289
Clonazepam70$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,190$21,92714 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$204$6,94413 claims
Almatica Pharma LLCSertraline Hcl$16$594105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →